Key result
A single injection of the virosomal hepatitis A vaccine Epaxal is highly immunogenic, providing 88-97% seroprotection 2 weeks after the first dose with fewer local reactions than aluminum vaccines.
Why the study?
Does virosome-formulated hepatitis A vaccine (Epaxal) improve tolerability while maintaining immunogenicity compared to aluminum-adsorbed vaccines?
Does virosome-formulated hepatitis A vaccine (Epaxal) improve tolerability while maintaining immunogenicity compared to aluminum-adsorbed vaccines?
Epaxal is a highly immunogenic virosomal hepatitis A vaccine that offers a better local tolerability profile than traditional aluminum-adjuvanted vaccines.
No takes yet. Share an insight, caveat, or question.
Summarizes Epaxal data; leaves open need for head-to-head trials versus aluminum-adjuvanted HAV vaccines.
Patrick Bovier (2008) conducted a review in Hepatitis A infection. Epaxal (virosomal hepatitis A vaccine) vs. Aluminum-adsorbed vaccine was evaluated on Seroprotection. A single injection of the virosomal hepatitis A vaccine Epaxal is highly immunogenic, providing 88-97% seroprotection 2 weeks after the first dose with fewer local reactions than aluminum vaccines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: